PURPOSE: To evaluate the efficacy and toxicity of pegylated liposomal doxorubicin in patients with advanced endometrial cancer. METHODS: Pegylated liposomal doxorubicin was administered at a dose of 40 mg/m2, and repeated on an every 28-day schedule. RESULTS: A total of 19 patients were enrolled in this phase 2 trial. Fourteen patients had received prior chemotherapy (carboplatin/paclitaxel-9; cisplatin/paclitaxel-3; single agent paclitaxel-2), seven prior radiation therapy, and three prior hormonal therapy. No patients had previously received doxorubicin. Two patients (11%) developed grade 1 hand-foot syndrome following treatment with pegylated liposomal doxorubicin. There were no episodes of cardiac dysfunction (>10% reduction in baseline ejection fraction). Three patients required hospitalization for nausea, vomiting, anemia, and dehydration. Only 2 (11%) patients required dose reduction. Four of 19 patients (21%; 95% CI: 3-39%) evaluable for response exhibited objective and subjective evidence of an antineoplastic effect of therapy (duration of responses: 2 months, 3 months, 4 months, 6+ months). CONCLUSION: The pegylated liposomal doxorubicin regimen employed in this trial exhibited an acceptable toxicity profile (cardiac dysfunction, hand-foot syndrome). Definite, although modest, antineoplastic activity in a patient population with recurrent or advanced endometrial cancer was documented.
PURPOSE: To evaluate the efficacy and toxicity of pegylated liposomal doxorubicin in patients with advanced endometrial cancer. METHODS: Pegylated liposomal doxorubicin was administered at a dose of 40 mg/m2, and repeated on an every 28-day schedule. RESULTS: A total of 19 patients were enrolled in this phase 2 trial. Fourteen patients had received prior chemotherapy (carboplatin/paclitaxel-9; cisplatin/paclitaxel-3; single agent paclitaxel-2), seven prior radiation therapy, and three prior hormonal therapy. No patients had previously received doxorubicin. Two patients (11%) developed grade 1 hand-foot syndrome following treatment with pegylated liposomal doxorubicin. There were no episodes of cardiac dysfunction (>10% reduction in baseline ejection fraction). Three patients required hospitalization for nausea, vomiting, anemia, and dehydration. Only 2 (11%) patients required dose reduction. Four of 19 patients (21%; 95% CI: 3-39%) evaluable for response exhibited objective and subjective evidence of an antineoplastic effect of therapy (duration of responses: 2 months, 3 months, 4 months, 6+ months). CONCLUSION: The pegylated liposomal doxorubicin regimen employed in this trial exhibited an acceptable toxicity profile (cardiac dysfunction, hand-foot syndrome). Definite, although modest, antineoplastic activity in a patient population with recurrent or advanced endometrial cancer was documented.
Authors: F M Muggia; J D Hainsworth; S Jeffers; P Miller; S Groshen; M Tan; L Roman; B Uziely; L Muderspach; A Garcia; A Burnett; F A Greco; C P Morrow; L J Paradiso; L J Liang Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: S M Campos; R T Penson; A R Mays; R S Berkowitz; A F Fuller; A Goodman; U A Matulonis; A Muzikansky; M V Seiden Journal: Gynecol Oncol Date: 2001-05 Impact factor: 5.482
Authors: B Uziely; S Jeffers; R Isacson; K Kutsch; D Wei-Tsao; Z Yehoshua; E Libson; F M Muggia; A Gabizon Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544
Authors: Rebecca Kristeleit; Victor Moreno; Valentina Boni; Eva M Guerra; Carmen Kahatt; Ignacio Romero; Emiliano Calvo; Neus Basté; José A López-Vilariño; Mariano Siguero; Vicente Alfaro; Ali Zeaiter; Martin Forster Journal: Int J Gynecol Cancer Date: 2021-10-05 Impact factor: 3.437
Authors: Heidi Rütten; Cornelia Verhoef; Willem Jan van Weelden; Anke Smits; Joëlle Dhanis; Nelleke Ottevanger; Johanna M A Pijnenborg Journal: Cancers (Basel) Date: 2021-12-14 Impact factor: 6.639